Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 319 participants.

Also called NCT01752985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 319 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01752985
  • EudraCT 2012-005093-54
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Denmark, France (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01752985. Randomized; double masking; primary purpose treatment. Start 2013-03-18 (actual); primary completion 2015-06-30 (actual). Results posted on 2019-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
Condition
Diabetic Kidney Disease
Intervention (Drug)
BMS-813160
Intervention (Drug)
Placebo matching with BMS-813160
Lead sponsor
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct01752985
Content hash
d48ad3c95233389571a5da275deae6ec8605889fa6780260d143bae2dc9d4389